Autosomal dominant spastic paraplegia type 38

Autosomal dominant spastic paraplegia type 38 (SPG38) is an extremely rare hereditary spastic paraplegia characterized by progressive spasticity and weakness of the lower limbs. Hereditary spastic paraplegias are a group of neurodegenerative disorders in which the primary pathology involves degeneration of the upper motor neurons, specifically the corticospinal tract axons. SPG38 primarily affects the nervous system, leading to difficulty walking due to increasing stiffness and weakness in the legs. It has been classified as a "pure" form of hereditary spastic paraplegia, meaning that spastic paraplegia is the predominant clinical feature without significant additional neurological or systemic involvement, though some patients may develop mild additional features. SPG38 was mapped to chromosome 4p16-p15 in a single family. The causative gene has not yet been definitively identified. Onset of symptoms has been reported in childhood to early adulthood, with a slowly progressive course. Affected individuals typically present with gait difficulties, lower limb spasticity, hyperreflexia, and extensor plantar responses (Babinski sign). Upper limbs are generally spared or minimally affected. There is currently no cure or disease-modifying treatment for SPG38. Management is symptomatic and supportive, focusing on physical therapy to maintain mobility and reduce spasticity, antispasticity medications such as baclofen or tizanidine, and orthopedic interventions as needed. Regular follow-up with a neurologist and rehabilitation specialist is recommended to optimize quality of life and functional independence.

Common questions about Autosomal dominant spastic paraplegia type 38